Response to hepatitis B vaccine in patients with multiple sclerosis: preliminary data

Garcés Redondo, Moisés (Universidad de Zaragoza) ; Val Lafaja, Alodia de (Universidad de Zaragoza) ; Atienza Ayala, Saida (Universidad de Zaragoza) ; Garcés Antón, Esther (Universidad de Zaragoza) ; Marín Gracia, Carmen Marta ; Román Calderón, Francisco ; López Mendoza, Héctor ; Chaure Pardos, Armando ; Hernández García, Ignacio ; Íñiguez Martínez, Cristina (Universidad de Zaragoza)

Resumen: Background
Studies in different autoimmune pathologies report a lower response rate (immunogenicity) to vaccinations than in the general population. Our objective is to analyze the immunogenicity of the vaccine against hepatitis B virus (HBV) in patients with multiple sclerosis (MS).
Methods
In a single prospective cohort of MS patients with negative HBV serology, hepatitis B (rDNA) B vaccine was administered at 0, 1 and 6 months. Immunogenicity was analyzed by the determination of antibodies to surface antigens of HBV. We considered a patient as a responder if antibodies level was higher than 10 IU/L. Posterior analysis of immunogenicity was conducted by demographic variables (e.g. MS phenotype, EDSS) and use of disease-modifying drugs (DMTs).
Results
Vaccination study of 251 patients: 160 of them were sero-negative (63.7%). Patients vaccinated: 99. Overall response: 74.1%. No significant relationship by sex (female 77.6% responders, male 68.8%) and MS phenotype (relapsing forms 74.3% responders, secondary progressive 50%). Variables associated with significantly lower immunogenicity were: age (>55 years), EDSS score (median: non-responders=3.0, responders=1.0), number of relapses and treatment with fingolimod (28.6% responders, n=7). Anti-CD20 therapies showed lower vaccine response (50%), but were not very represented in our sample (n=2). Immunogenicity with other DMTs: interferon/glatiramer 69.6% (n=23), teriflunomide 71.4% (n=14), dimethylfumarate 92.3% (n=13), natalizumab 100% (n=7).
Conclusion
The overall immunogenicity of our sample is lower than that reported in the general population (74 vs >86%), as in other autoimmune diseases. Preliminary data show a lower immunogenicity with older age, higher EDSS score, number of relapses and fingolimod use.

Idioma: Inglés

DOI: 10.1016/j.msard.2021.102995

Año: 2021

Publicado en: Multiple Sclerosis and Related Disorders 51 (2021), 102995 [2 pp.]
ISSN: 2211-0348

Factor impacto JCR: 4.808 (2021)

Categ. JCR: CLINICAL NEUROLOGY rank: 64 / 212 = 0.302 (2021) - Q2 - T1

Factor impacto CITESCORE: 5.0 - Neuroscience (Q2) - Medicine (Q2)

Factor impacto SCIMAGO: 1.006 - Neurology (Q1) - Medicine (miscellaneous) (Q1)

Tipo y forma: Comunicación congreso (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)